SIBNHealthcare · Medical DevicesThe 9 Wall Street analysts covering SI-BONE, Inc. hold a median 12-month price target of $25 — +17.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 31 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores SI-BONE, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (79): The business earns solid, repeatable profits on what it owns.
Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SIBN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.5% from it.
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Truist Securities | Maintains | Buy | $23 → $25 |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | $18 → $20 |
| 4 Aug 2026 | Truist Securities | Reiterates | Buy | — |
| 4 Aug 2026 | Truist Securities | Reiterates | Buy | $21 → $23 |
| 4 Aug 2026 | UBS | Maintains | Buy | $24 → $25 |
| 4 Aug 2026 | UBS | Maintains | Buy | — |
| 28 July 2026 | UBS | Initiates | Buy | $24 |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | $18 → $21 |
| 12 May 2026 | TD Cowen | Maintains | Buy | $22 → $18 |
| 12 May 2026 | TD Cowen | Maintains | Buy | — |
| 12 May 2026 | Truist Securities | Reiterates | Buy | $20 → $18 |
| 12 May 2026 | Truist Securities | Reiterates | Buy | — |
| 15 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 24 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 24 Feb 2026 | Truist Securities | Reiterates | Buy | — |
| 27 Jan 2026 | TD Cowen | Initiates | Buy | — |
| 18 Dec 2025 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SIBN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, SI-BONE, Inc. returned +40.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 26% of US stocks
Cheaper than 18% of US stocks
Cheaper than 96% of US stocks
Higher than 63% of US stocks
Higher than 54% of US stocks
Higher than 90% of US stocks
Higher than 25% of US stocks
Higher than 22% of US stocks
Higher than 37% of US stocks
Higher than 33% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
SI-BONE, Inc. has a market value of $941.5M and an enterprise value of $848.4M.
Revenue in the twelve months to 30 June 2026: $213.6M. The latest quarter grew 15.2% year on year.
Net income over the same four quarters: −$14.6M, a −6.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.34.
Free cash flow in the twelve months to 30 June 2026: −$4.4M.
Trailing P/E: −48.3×; forward P/E: −64.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
SI-BONE, Inc. employs 376 people — $568K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SI-BONE, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SI-BONE announced it will participate in the UBS Global Healthcare Conference in Palm Beach Gardens, Florida. Management is scheduled to host a fireside chat on November 10, 2026, at 2:00 p.m. Pacific / 5:00 p.m. Eastern.
Why it matters — SIBN watchers may note the scheduled opportunity to hear from management at the healthcare conference.
SI-BONE announced it will report third-quarter 2026 financial results after market close on November 2, 2026. Management will host a conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Why it matters — SIBN watchers can note the date and time when the company plans to release results and discuss them with management.
SI-BONE announced it received FDA 510(k) clearance for its iFuse Granite Onyx implant, extending its compromised bone franchise beyond the pelvis. The platform, which received FDA Breakthrough Device Designation, is engineered for durable fixation in low-density bone.
Why it matters — FDA clearance expands SI-BONE's addressable product portfolio into new anatomical areas beyond its established pelvic franchise.
SI-BONE, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation is now available via Seeking Alpha.
Why it matters — The conference presentation gives SI-BONE watchers direct visibility into the company's latest corporate updates and strategic messaging as delivered to the investment community.
SI-BONE, Inc. announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, where management will host a fireside chat on September 14, 2026, at 8:30 a.m. Pacific Time.
Why it matters — The upcoming fireside chat gives investors an opportunity to hear SI-BONE management discuss the company directly at a major healthcare investment conference.
The 9 Wall Street analysts covering SI-BONE, Inc. have a median 12-month price target of $25, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering SI-BONE, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SI-BONE, Inc. 72 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, SI-BONE, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (79 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +17.5% from the last close, and Ticker Nerd's factor model ranks SI-BONE, Inc. 72 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering SI-BONE, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SIBN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.
SI-BONE, Inc. returned +40.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
SI-BONE, Inc. is a medical device company focused on developing procedural solutions for musculoskeletal disorders of the sacropelvic anatomy.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026". SI-BONE announced it will participate in the UBS Global Healthcare Conference in Palm Beach Gardens, Florida. Management is scheduled to host a fireside chat on November 10, 2026, at 2:00 p.m. Pacific / 5:00 p.m. Eastern.
SI-BONE, Inc. is a medical device company focused on developing procedural solutions for musculoskeletal disorders of the sacropelvic anatomy. SI-BONE’s product portfolio centers on minimally invasive implant systems designed for sacroiliac joint fusion, pelvic fixation, and related orthopedic applications. Its offerings include patented titanium implants, surgical instruments, and implantable bone products used in procedures addressing sacroiliac joint dysfunction, pelvic trauma, and spinopelvic reconstruction. The company serves physicians and hospitals in the United States and selected international markets, supporting treatment workflows through direct sales and third-party distribution channels. Based in Santa Clara, California, SI-BONE plays a specialized role in the orthopedics and spine market by providing anatomy-specific technologies for patients with complex bone and joint conditions.
CEO Ms. Laura A. Francis MBA · 376 employees · United States · https://si-bone.com
